Senti Biosciences Faces Delisting Notice

TL;DR

Senti Bio got a delisting notice, might get kicked off the exchange.

AI Summary

Senti Biosciences, Inc. filed an 8-K on October 25, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The earliest event reported was on October 22, 2024. The company is incorporated in Delaware and its principal executive offices are located in South San Francisco, California.

Why It Matters

This filing indicates Senti Biosciences may be at risk of being removed from its stock exchange, which could significantly impact its stock price and ability to raise capital.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet listing standards is a severe warning that can lead to stock suspension and trading halt.

Key Players & Entities

• Senti Biosciences, Inc. (company) — Registrant
• October 25, 2024 (date) — Filing Date
• October 22, 2024 (date) — Earliest Event Date
• Delaware (jurisdiction) — State of Incorporation
• South San Francisco, California (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share SNTI The Nasdaq Capital Marke

Filing Documents

• snti-20241022.htm (8-K) — 29KB
• 0001854270-24-000108.txt ( ) — 154KB
• snti-20241022.xsd (EX-101.SCH) — 2KB
• snti-20241022_lab.xml (EX-101.LAB) — 22KB
• snti-20241022_pre.xml (EX-101.PRE) — 13KB
• snti-20241022_htm.xml (XML) — 3KB

01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On October 21, 2024, Senti Biosciences, Inc., a Delaware corporation (the "Company"), notified the Nasdaq Stock Market LLC ("Nasdaq") that the Company is not in compliance with the audit committee requirement under Nasdaq Listing Rule 5605(c)(2)(A) due to the Company having only two members on its audit committee (the "Audit Committee") of its Board of Directors (the "Board") solely due to a vacancy resulting from Susan Berland's resignation from the Board effective June 11, 2024 as previously disclosed in Part II, Item 5 of the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2024. On October 22, 2024, the Company received a notice (the "Notice") from Nasdaq indicating that the Company no longer complies with the audit committee requirements as set forth in Nasdaq Listing Rule 5605. The Company has the opportunity to regain compliance within the cure period provided in Nasdaq Listing Rule 5605(c)(4), as follows: (i) until the earlier of the Company's next annual meeting of stockholders or June 11, 2025; or (ii) December 9, 2024, because the Company's next annual stockholders' meeting was held before December 9, 2024. The Company is evaluating the membership of the Audit Committee and intends to regain compliance with Nasdaq Listing Rule 5605(c)(2)(A) prior to the expiration of the applicable cure period described above. The Notice has no immediate effect on the listing or trading of the Company's common stock on The Nasdaq Capital Market. Cautionary Note Regarding Forward Looking Statements This Current Report on Form 8-K and other related materials may contain a number of "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the Company's expectation about any or all of the following: (i) the intent and plan of the Company to reg

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SENTI BIOSCIENCES, INC. Date: October 25, 2024 By: /s/ Timothy Lu Name: Timothy Lu, M.D., Ph.D. Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR